Anti-CD30 Antibody-drug Conjugate SGN-35C

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of brentuximab (cAC10), a chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor necrosis factor (TNF) receptor CD30 (tumor necrosis factor receptor superfamily, member 8; TNFRSF8), conjugated to a camptothecin-derived topoisomerase 1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration, anti-CD30 ADC SGN-35C targets and binds to CD30 expressed on tumor cells. Upon binding and internalization, the TOP1i moiety is released, binds to TOP1 and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of CD30-expressing tumor cells. CD30 may be constitutively expressed in certain B- and T-cell lymphoma while expression is limited in normal, healthy cells.

**Synonyms:** - ADC SGN-35C - Anti-CD30 ADC SGN-35C - Anti-CD30/TOP1i ADC SGN-35C - SGN 35C - SGN-35C - SGN35C